Ainos (NASDAQ:AIMD) Major Shareholder Carbon Nano Technology Taiwan Sells 46,000 Shares of Stock

Ainos, Inc. (NASDAQ:AIMD) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total value of $99,820.00. Following the transaction, the insider directly owned 989,925 shares of the company’s stock, valued at $2,148,137.25. This trade represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Carbon Nano Technology Taiwan also recently made the following trade(s):

• On Friday, January 9th, Carbon Nano Technology Taiwan sold 431 shares of Ainos stock. The stock was sold at an average price of $1.86, for a total value of $801.66.
• On Thursday, January 8th, Carbon Nano Technology Taiwan sold 850 shares of Ainos stock. The stock was sold at an average price of $1.80, for a total value of $1,530.00.

Ainos Price Performance

Shares of NASDAQ AIMD opened at $2.35 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.96 and a quick ratio of 2.67. The firm has a market capitalization of $11.30 million, a PE ratio of -0.59 and a beta of 2.45. Ainos, Inc. has a 1-year low of $1.61 and a 1-year high of $4.50. The business’s fifty day moving average price is $1.99 and its two-hundred day moving average price is $2.85.

Ainos (NASDAQ:AIMD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter. The firm had revenue of $0.00 million for the quarter.

Institutional Trading of Ainos

A hedge fund recently bought a new stake in Ainos stock. Two Sigma Investments LP acquired a new stake in Ainos, Inc. (NASDAQ:AIMD) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned 0.48% of Ainos as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.